ATE500218T1 - Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff - Google Patents
Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoffInfo
- Publication number
- ATE500218T1 ATE500218T1 AT02747707T AT02747707T ATE500218T1 AT E500218 T1 ATE500218 T1 AT E500218T1 AT 02747707 T AT02747707 T AT 02747707T AT 02747707 T AT02747707 T AT 02747707T AT E500218 T1 ATE500218 T1 AT E500218T1
- Authority
- AT
- Austria
- Prior art keywords
- bone
- agonist
- treatment
- diseases associated
- active ingredient
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 206010065687 Bone loss Diseases 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 210000000988 bone and bone Anatomy 0.000 abstract 4
- 208000001132 Osteoporosis Diseases 0.000 abstract 2
- 230000011164 ossification Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031264 Osteonecrosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 125000003259 prostaglandin group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pregnancy & Childbirth (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001222148 | 2001-07-23 | ||
JP2001239895 | 2001-08-07 | ||
JP2002056449 | 2002-03-01 | ||
PCT/JP2002/007385 WO2003009872A1 (en) | 2001-07-23 | 2002-07-22 | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE500218T1 true ATE500218T1 (de) | 2011-03-15 |
Family
ID=27347210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02747707T ATE500218T1 (de) | 2001-07-23 | 2002-07-22 | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff |
Country Status (22)
Country | Link |
---|---|
US (3) | US7608637B2 (de) |
EP (2) | EP2255829A3 (de) |
JP (3) | JP4273407B2 (de) |
KR (3) | KR20070043059A (de) |
CN (1) | CN101921220B (de) |
AT (1) | ATE500218T1 (de) |
AU (1) | AU2002318759C1 (de) |
BR (1) | BR0211364A (de) |
CA (1) | CA2454584C (de) |
DE (1) | DE60239343D1 (de) |
DK (1) | DK1417975T3 (de) |
HU (1) | HU230421B1 (de) |
IL (1) | IL159996A0 (de) |
MX (1) | MXPA04000757A (de) |
NO (2) | NO332625B1 (de) |
NZ (1) | NZ530885A (de) |
PL (1) | PL367740A1 (de) |
PT (1) | PT1417975E (de) |
RU (1) | RU2303451C2 (de) |
TW (1) | TWI313608B (de) |
WO (1) | WO2003009872A1 (de) |
ZA (1) | ZA200400493B (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
MXPA04000757A (es) * | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
US20040204590A1 (en) * | 2001-12-03 | 2004-10-14 | Ogidigben Miller J. | Ep4 receptor agonist, compositions and methods thereof |
TW200305425A (en) | 2002-03-05 | 2003-11-01 | Ono Pharmaceutical Co | 8-Azaprostaglandin derivatives and medicament containing same as active ingredient |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
JP2005534653A (ja) * | 2002-06-06 | 2005-11-17 | メルク フロスト カナダ アンド カンパニー | 眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体 |
US7419999B2 (en) | 2002-06-10 | 2008-09-02 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
US7109223B2 (en) * | 2002-08-28 | 2006-09-19 | Merck & Co. Inc. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma |
WO2004037813A1 (en) * | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
CA2502914A1 (en) * | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | 2-pyrrolidones as ep4 receptor agonists |
EP1586564B1 (de) * | 2003-01-21 | 2012-11-28 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandinderivate und deren medizinische verwendung |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
WO2005053707A1 (ja) | 2003-12-05 | 2005-06-16 | Ono Pharmaceutical Co., Ltd. | 馬尾神経組織血流増加剤 |
WO2005072743A1 (ja) * | 2004-01-30 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 気管支拡張剤 |
WO2006016695A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 |
JP4888775B2 (ja) * | 2004-08-10 | 2012-02-29 | 小野薬品工業株式会社 | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
JP4893999B2 (ja) * | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
CA2585367A1 (en) * | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
WO2006052893A2 (en) | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
EP1824819B1 (de) | 2004-12-06 | 2010-01-20 | Merck Serono SA | Pyrrolidin-2-on-Derivate zur Verwendung als DP1-Rezeptoragonisten |
EP1878429B1 (de) | 2005-04-28 | 2011-08-03 | Ono Pharmaceutical Co., Ltd. | Präparat zur transdermalen absorption |
EP2494990A1 (de) | 2005-06-03 | 2012-09-05 | Ono Pharmaceutical Co., Ltd. | Wirkstoff zur Regenerierung und/oder zum Schutz von Nerven |
US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
US7491844B2 (en) * | 2006-05-04 | 2009-02-17 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
US7476755B2 (en) * | 2006-05-04 | 2009-01-13 | Allergan, Inc. | Therapeutic compounds |
US8410171B2 (en) * | 2006-10-26 | 2013-04-02 | Ono Pharmaceutical Co., Ltd. | Adhesive preparation |
WO2008058766A1 (en) | 2006-11-16 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
EP2147672A4 (de) | 2007-05-08 | 2011-11-02 | Nat University Corp Hamamatsu University School Of Medicine | Zytotoxischer t-zellen-aktivator mit einem ep4-agonisten |
EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
JP5557216B2 (ja) * | 2009-03-13 | 2014-07-23 | 国立大学法人 東京大学 | 多官能性化合物及びそれを用いて得られるヘテロ原子ポリマーならびにそれらの製造方法 |
DK2441760T3 (en) | 2009-06-10 | 2014-02-17 | Ono Pharmaceutical Co | A compound of bladder muscle contraction activity and activity urinrørsmuskelafslappende |
JP2013508282A (ja) | 2009-10-14 | 2013-03-07 | ジェンムス ファーマ インコーポレイティド | ウイルス感染のための併用療法処置 |
KR200457847Y1 (ko) * | 2010-02-12 | 2012-01-06 | 김인주 | 케이블 정리밴드 |
BR112013002319A2 (pt) * | 2010-07-30 | 2016-05-24 | Allergan Inc | compostos e métodos para reparo da pele |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
CA2827615A1 (en) | 2011-02-17 | 2012-08-23 | Dennis E. Van Epps | Compositions and improved soft tissue replacement methods |
EP2678022A2 (de) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe |
AU2012290987B2 (en) * | 2011-08-02 | 2017-04-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
WO2013123270A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814510A1 (de) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe |
CN104640542B (zh) | 2012-07-19 | 2017-09-22 | 开曼化学股份有限公司 | 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物 |
RU2503458C1 (ru) * | 2012-08-27 | 2014-01-10 | Сергей Васильевич Чуйкин | Способ местного лечения и профилактики основных стоматологических заболеваний у детей с хронической почечной недостаточностью с применением жевательного фитосубстрата |
US9643940B2 (en) | 2012-08-31 | 2017-05-09 | Ono Pharmaceutical Co., Ltd. | Amine salt and crystals thereof |
CN105143217A (zh) | 2013-03-15 | 2015-12-09 | 开曼化学股份有限公司 | 作为ep4受体选择性激动剂的内酰胺化合物用于治疗ep4介导的疾病和病症 |
AU2014229065B2 (en) * | 2013-03-15 | 2017-03-09 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
CA2920856A1 (en) | 2013-08-09 | 2015-02-12 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
US10988468B2 (en) | 2017-12-25 | 2021-04-27 | Asahi Kasei Pharma Corporation | Nitrogen-containing 6-membered cyclic compound |
JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (de) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
JPS503362B1 (de) | 1970-06-10 | 1975-02-04 | ||
US4054736A (en) * | 1970-06-10 | 1977-10-18 | Ono Pharmaceutical Co., Ltd. | Clathrate compounds of prostaglandins or their analogues with cyclodextrin |
JPS5231404B1 (de) | 1971-04-28 | 1977-08-15 | ||
US3975399A (en) * | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
US4113873A (en) * | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
DE2556326A1 (de) | 1975-12-13 | 1977-06-23 | Hoechst Ag | Neue pyrrolidone und verfahren zu ihrer herstellung |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) * | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
US4320136A (en) * | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
JPS57156460A (en) | 1981-03-20 | 1982-09-27 | Ono Pharmaceut Co Ltd | Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation |
SE9702681D0 (sv) | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
SK3412000A3 (en) | 1997-09-09 | 2000-12-11 | Procter & Gamble | Method of increasing bone volume using non-naturally-occurring fp selective agonists |
GB2330307A (en) | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
JP3703004B2 (ja) * | 1998-07-15 | 2005-10-05 | 小野薬品工業株式会社 | 5−チア−ω−置換フェニル−プロスタグランジンE誘導体 |
TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6414006B1 (en) * | 1998-10-15 | 2002-07-02 | Merck Frosst Canada & Co. | Methods for inhibiting bone resorption |
EP1148877A4 (de) | 1998-10-15 | 2003-01-22 | Merck & Co Inc | Verfahren zur hemmung der knochenresorption |
JP2002527400A (ja) * | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨形成刺激方法 |
US6211226B1 (en) * | 1998-12-17 | 2001-04-03 | Alcon Laboratories, Inc. | 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
EP1080728A1 (de) | 1999-03-16 | 2001-03-07 | Toray Industries, Inc. | Prostaglandin ep4 rezeptor agonist und behandlungsverfahren |
TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
BR0016560A (pt) | 1999-12-22 | 2002-09-10 | Pfizer Prod Inc | Agonistas seletivos do receptor ep4 no tratamento da osteoporose |
ATE327751T1 (de) * | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
WO2001062724A1 (fr) | 2000-02-28 | 2001-08-30 | Taisho Pharmaceutical Co., Ltd. | Derives de prostaglandine e |
AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
EP1339678B1 (de) | 2000-11-27 | 2007-09-26 | Pfizer Products Inc. | Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose |
DK1408961T3 (da) * | 2001-07-16 | 2007-11-05 | Hoffmann La Roche | 2 pyrrolidon-derivater som prostanoide agonister |
MXPA04000757A (es) * | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
-
2002
- 2002-07-22 MX MXPA04000757A patent/MXPA04000757A/es active IP Right Grant
- 2002-07-22 HU HU0600140A patent/HU230421B1/hu not_active IP Right Cessation
- 2002-07-22 KR KR1020077007791A patent/KR20070043059A/ko not_active Application Discontinuation
- 2002-07-22 AT AT02747707T patent/ATE500218T1/de active
- 2002-07-22 JP JP2003515264A patent/JP4273407B2/ja not_active Expired - Fee Related
- 2002-07-22 RU RU2004105154/15A patent/RU2303451C2/ru not_active IP Right Cessation
- 2002-07-22 CA CA002454584A patent/CA2454584C/en not_active Expired - Fee Related
- 2002-07-22 WO PCT/JP2002/007385 patent/WO2003009872A1/ja active Application Filing
- 2002-07-22 EP EP10176842A patent/EP2255829A3/de not_active Withdrawn
- 2002-07-22 EP EP02747707A patent/EP1417975B1/de not_active Expired - Lifetime
- 2002-07-22 AU AU2002318759A patent/AU2002318759C1/en not_active Ceased
- 2002-07-22 US US10/484,500 patent/US7608637B2/en not_active Expired - Fee Related
- 2002-07-22 PT PT02747707T patent/PT1417975E/pt unknown
- 2002-07-22 TW TW091116219A patent/TWI313608B/zh not_active IP Right Cessation
- 2002-07-22 DE DE60239343T patent/DE60239343D1/de not_active Expired - Lifetime
- 2002-07-22 IL IL15999602A patent/IL159996A0/xx not_active IP Right Cessation
- 2002-07-22 CN CN2010102514340A patent/CN101921220B/zh not_active Expired - Fee Related
- 2002-07-22 NZ NZ530885A patent/NZ530885A/en not_active IP Right Cessation
- 2002-07-22 KR KR1020077016142A patent/KR20070087078A/ko not_active Application Discontinuation
- 2002-07-22 BR BR0211364-3A patent/BR0211364A/pt active Search and Examination
- 2002-07-22 PL PL02367740A patent/PL367740A1/xx unknown
- 2002-07-22 KR KR1020047000997A patent/KR100826866B1/ko not_active IP Right Cessation
- 2002-07-22 DK DK02747707.4T patent/DK1417975T3/da active
-
2004
- 2004-01-22 ZA ZA2004/00493A patent/ZA200400493B/en unknown
- 2004-01-23 NO NO20040331A patent/NO332625B1/no not_active IP Right Cessation
-
2008
- 2008-12-25 JP JP2008329756A patent/JP4973650B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-27 US US12/549,136 patent/US8207223B2/en not_active Expired - Fee Related
-
2011
- 2011-12-22 NO NO20111765A patent/NO20111765L/no not_active Application Discontinuation
-
2012
- 2012-01-16 JP JP2012006534A patent/JP5387699B2/ja not_active Expired - Fee Related
- 2012-04-23 US US13/453,434 patent/US20120202773A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE500218T1 (de) | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff | |
BR0100558A (pt) | Composições e métodos para tratar a osteoporose | |
MY146809A (en) | Treatment and prevention of osteoporosis | |
LU91281I2 (fr) | Preotact-hormone parathyroïde | |
SE9901272D0 (sv) | New improved formulation | |
EP1232757A4 (de) | Mittel für erkrankungen assoziert mit knochensubstanzverlust | |
DE69501419T2 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol | |
DE60233803D1 (de) | 5-cnac zur oralen verabreichung von parathormonfragmenten | |
BR9808233A (pt) | Preparação farmacêutica | |
DE60212621D1 (de) | Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis | |
DE69916932D1 (de) | Kombinationstherapeutika, enthaltend einen selektiven Östrogenrezeptormodulator und Prostaglandin E2 | |
DE69915852D1 (de) | Lhrh-analoga zur behandlung der osteoporose | |
TH48282A (th) | การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1417975 Country of ref document: EP |